𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The development of magnetic degradable DP-Bioglass for hyperthermia cancer therapy

✍ Scribed by Tzu-Wei Wang; Hsi-Chin Wu; Wei-Ren Wang; Feng-Huei Lin; Pei-Jen Lou; Ming-Jium Shieh; Tai-Horng Young

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
418 KB
Volume
83A
Category
Article
ISSN
1549-3296

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In this study, a novel magnetic degradable material was developed by adding Fe ions into DP‐Bioglass (Na~2~O‐CaO‐P~2~O~5~‐SiO~2~) as thermoseed for hyperthermia cancer therapy under an alternating magnetic field. We have investigated the properties of developed magnetic DP‐Bioglass including morphology, chemical composition, and magnetism. The degradability was conducted by measuring the released concentrations of Na, Ca, Si, P, and Fe ions. The biocompatibility was analyzed by biological assays, and the functional hyperthermia effect to cancer cells was evaluated by in vitro cell culture test. In the results, the morphology of synthesized magnetic DP‐Bioglass was revealed in sphere and rod shape with particle size around 50–100 nm. From the hysteresis loop analysis, it showed that the group of Fe/Bioglass = 0.2 possessed the maximum magnetization property. When cultured with fibroblasts, the magnetic DP‐Bioglass had no significant influence on cell viability and mediated low cytotoxicity. The thermal‐induced property demonstrated that after exposure to an alternating magnetic field, the cell number of human Caucasian lung carcinoma cells (A549) was significantly decreased when temperature was increasing to 45°C. In brief, successfully incorporated with Fe ions by sol‐gel method, this magnetic degradable DP‐Bioglass possessed the potential and properties of hyperthermia effect to lung carcinoma cells. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2007

📜 SIMILAR VOLUMES

Effect of hyperthermia on TRAIL-induced
Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: Development of a novel strategy for regional therapy
✍ Jinsang Yoo; Yong J. Lee 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 2 views

## Abstract Approximately 25% of patients with colorectal cancer will develop metastatic disease exclusively or largely confined to the liver, and the vast majority of these cases are not amenable to surgical resection. These unresectable cases of liver metastatic disease can be treated with isolat

ChemInform Abstract: The Role of Inorgan
ChemInform Abstract: The Role of Inorganic Chemistry in the Development of Radiometal Agents for Cancer Therapy
✍ Mary Jane Heeg; Silvia S. Jurisson 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 24 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Gene-directed enzyme prodrug therapy for
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease
✍ Rosetta Martiniello-Wilks; Allison Dane; Dale J. Voeks; Geetha Jeyakumar; Elin M 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB 👁 1 views

## Abstract ## Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar

Pretreatment prostate-specific antigen v
Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy
✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a